Chime Financial, Inc. is a San Francisco-based financial technology company that provides digital consumer banking and payment services through its proprietary platform in partnership with third-party banks. Its product ecosystem includes spending and checking accounts, a debit card, fee-free overdraft through SpotMe, MyPay earned-wage access, Instant Loans, a Credit Builder card, high-yield savings, Pay Anyone, Chime Workplace, and the recently launched Chime Invest. Chime completed its initial public offering on the Nasdaq on June 12, 2025. With 10.4 million active members at the end of June 2026, the company positions itself as a primary-account alternative to traditional banks, emphasizing lower cost-to-serve and deeper member engagement across a growing suite of financial products.
CHYM closed at $31.91 on Aug. 18, 2026, up 1.5% for the session. Thirty calendar days earlier, the stock closed at $21.93 on July 20, 2026, which translates to a gain of approximately 45.5% over the period. The advance was not linear: shares climbed into the Aug. 5 earnings report, then jumped about 20.6% on Aug. 6, from $25.92 to $31.25, on volume of roughly 19.3 million shares compared with a typical daily average near 6 million. The Aug. 6 session also produced an intraday high of $33.41, which stands as the 52-week high.
The quarterly picture is even more pronounced. From the May 19 close of $16.91 to the Aug. 18 close of $31.91, CHYM gained about 88.7%. The shares set a 52-week intraday low of $15.88 on June 11 before recovering, so the three-month move reflects both a rebound from depressed levels and a post-earnings re-rating. I also checked this using Tickeron’s AI Pattern Search Engine to see how the move compared with similar post-earnings patterns in the sector.
The dominant catalyst was Chime's second-quarter earnings report, released Aug. 5. Revenue rose 27% year over year to $669.8 million, ahead of consensus estimates near $641 million. Adjusted EBITDA reached $102 million, with the adjusted EBITDA margin expanding 12 percentage points year over year to 15%, and the company reported $28 million in GAAP net income, its second consecutive quarter of positive GAAP earnings.
Management also raised its full-year outlook, citing accelerating momentum. Chime now projects 25% to 26% revenue growth for 2026 and adjusted EBITDA between $465 million and $475 million. For the third quarter, the company guided to revenue of $680 million to $690 million and adjusted EBITDA of $105 million to $110 million.
Product momentum reinforced the earnings story. Chime Prime, launched in early April for members with at least $3,000 in monthly qualifying direct deposits, has drawn higher-income consumers and Prime members generate more than double the average member ARPAM. MyPay originations reached $4.5 billion with transaction profit tripling year over year to $73 million, while Instant Loans originations grew nearly 70% quarter over quarter to $300 million. Chime also announced enterprise wins with Allied Universal, which has about 320,000 North American employees, and a national retailer with roughly 35,000 employees.
Over the trailing three months, the narrative shifted from post-IPO skepticism to profitable growth. After going public in June 2025, Chime shares traded below their IPO price into spring 2026, pressured by questions about the company's path to consistent profitability. The company answered those questions first with its initial GAAP quarterly profit in Q1 2026 and then with a stronger Q2, turning investor attention toward operating leverage, transaction profit, and member monetization.
Broader product expansion also supported the quarterly trend. The April launch of Chime Prime, the July introduction of Chime Invest, higher MyPay limits, and a $500 million warehouse facility arranged with Goldman Sachs all contributed to a growth-oriented narrative. The combination of accelerating revenue, expanding margins, and consecutive profitable quarters helped CHYM nearly double from its mid-May levels.
Investors should monitor whether Chime can sustain its raised growth and profitability targets. The next quarterly report is estimated for early November 2026, and execution against the company's third-quarter guidance will be a key test. The ramp of Chime Prime, including rewards-cost moderation, will be closely watched alongside the rollout of higher MyPay limits of up to $1,000, which management said could modestly lift loss rates before being offset by higher transaction profit.
Other factors include the Instant Loans run-rate target of more than $100 million exiting Q3, the beta launch of a revolving line of credit, Chime Invest adoption, and the enterprise pipeline, which is expected to contribute more meaningfully to direct-depositor growth in 2027. Macroeconomic and consumer-spending conditions, regulatory oversight, and the announced CFO transition also remain important monitoring points for the stock. From what I see, tracking these elements will help clarify whether the recent re-rating holds.
In my own research process, I often turn to Tickeron’s AI Trading Bots to test quantitative strategies across different timeframes and risk profiles. The platform lets users review top-performing bots that trade thousands of tickers, helping filter for approaches that align with current market conditions rather than relying on a single signal. I find it useful for comparing rule-based ideas alongside traditional fundamental analysis, especially when evaluating momentum names like CHYM. AI Trading Bots provides a practical way to explore these options without committing capital upfront.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CHYM declined for three days, in of 63 cases, the price declined further within the following month. The odds of a continued downward trend are .
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
CHYM broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on CHYM as a result. In of 18 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CHYM just turned positive on July 31, 2026. Looking at past instances where CHYM's MACD turned positive, the stock continued to rise in of 7 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHYM advanced for three days, in of 54 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 29 cases where CHYM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CHYM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.834) is normal, around the industry mean (28.722). P/E Ratio (6.101) is within average values for comparable stocks, (79.317). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.755). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (5.157) is also within normal values, averaging (78.705).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHYM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows